Crohn's Disease Treatment in India & UAE — Biologics & Surgery from $1,000
Crohn's disease treatment in India from $1,000. Biologics, immunomodulators & bowel resection for Crohn's disease by expert gastroenterology teams. Book with GAF Healthcare.
Estimated cost: $1,000 – $8,000 · Average stay: 2–10 days
Crohn's disease is a chronic, relapsing-remitting transmural inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to anus, most commonly the terminal ileum and right colon. Unlike ulcerative colitis (which is limited to the colon's mucosal layer), Crohn's disease is characterised by transmural (full-thickness) inflammation — affecting all layers of the bowel wall — leading to complications that are unique to Crohn's and not seen in ulcerative colitis: fistulae (abnormal connections between the bowel and adjacent structures), strictures (bowel narrowing causing obstruction), abscesses, and perianal disease.
The aetiology of Crohn's disease is complex — an inappropriate, dysregulated immune response to intestinal microbiota in genetically susceptible individuals, triggered and perpetuated by environmental factors (smoking, gut microbiome dysbiosis, high-fat/low-fibre Western diet, early-life antibiotic exposure). Over 200 genetic susceptibility loci have been identified, with NOD2 (also called CARD15) the most replicated — variants in NOD2 are present in approximately 15–20% of European Crohn's disease patients and are associated with ileal disease location and complicated (stricturing/penetrating) disease behaviour.
India and the UAE have gastroenterologists with specific inflammatory bowel disease expertise and access to the full armamentarium of IBD therapies — including biologics that are available as highly cost-effective biosimilars in India — making India an increasingly important destination for Crohn's disease management.
Crohn's Disease Assessment
Crohn's disease is classified by the Montreal classification: age of onset (A1: under 16; A2: 17–40; A3: over 40); location (L1: ileal; L2: colonic; L3: ileocolonic; L4: upper GI tract modifier); and behaviour (B1: non-stricturing non-penetrating; B2: stricturing; B3: penetrating/fistulising; p modifier: perianal disease).
Assessment includes: ileocolonoscopy with biopsy (confirming the diagnosis, characterising disease location and activity, assessing response to treatment); upper endoscopy and small bowel imaging (MR enterography — the gold standard for assessing small bowel disease extent and detecting transmural complications: fistulae, abscesses, strictures); and MRI pelvis (for perianal fistula characterisation — defining fistula tract anatomy for surgical planning). Blood tests: CRP, ESR, FBC (anaemia), albumin, B12, folate, iron (nutritional deficiencies from malabsorption); faecal calprotectin (a sensitive mucosal inflammation marker — guides treatment decisions and monitoring).
Disease activity is assessed by the Harvey-Bradshaw Index (HBI) or Crohn's Disease Activity Index (CDAI) for clinical activity; C-reactive protein and faecal calprotectin for biochemical activity; and MRI/endoscopy for deep mucosal and transmural healing (the target of modern treat-to-target strategies).
Crohn's Disease Treatment
Crohn's disease management requires a stratified, individualised approach. The principle of "treat-to-target" — setting a clear therapeutic goal (mucosal and transmural healing, not just symptom control) and escalating therapy to achieve that goal — has replaced symptom-based management.
Aminosalicylates (5-ASA — mesalazine) have no proven benefit in Crohn's disease (unlike in ulcerative colitis) and are not used.
Corticosteroids (prednisolone, budesonide) are effective for inducing remission of acute Crohn's flares but have no role in maintenance — their significant systemic side effects (osteoporosis, diabetes, adrenal suppression, infection) make long-term use unacceptable. Budesonide (a gut-specific, high-first-pass hepatic metabolism steroid) is preferred for ileocaecal disease with fewer systemic effects.
Immunomodulators (thiopurines — azathioprine or 6-mercaptopurine; or methotrexate) are maintenance therapies that reduce relapse frequency. They have a slow onset of action (3–6 months) and are most effective as combination therapy with anti-TNF biologics.
Biological therapies are the most effective medical treatments for moderate-severe Crohn's disease: Anti-TNF agents — infliximab (IV infusion every 8 weeks after induction) and adalimumab (subcutaneous injection every 2 weeks) achieve mucosal healing in approximately 40–50% of patients. Vedolizumab (anti-integrin — gut-selective biological) achieves remission in approximately 35–40% of anti-TNF-naive patients and is preferred in patients with extra-intestinal manifestations where a gut-selective mechanism is advantageous. Ustekinumab (anti-IL-12/23) is effective in anti-TNF-refractory patients and has a favourable safety profile. Risankizumab and mirikizumab (anti-IL-23) are newer approved biologics. Ozanimod and filgotinib (small molecule agents) are emerging options.
Surgery (bowel resection, strictureplasty, abscess drainage, fistula repair, perianal disease treatment) is required in approximately 50–70% of Crohn's patients at some point in their disease course — most commonly for bowel obstruction from strictures, medically refractory disease, or perianal complications. Laparoscopic ileocaecal resection for terminal ileal Crohn's disease is associated with faster recovery and lower recurrence rates than open surgery, and achieves disease control equivalent to maximally intensive medical therapy for isolated ileocaecal disease in the LIRIC trial.
Procedure Steps
- Ileocolonoscopy with biopsy; MR enterography for small bowel assessment; MRI pelvis (if perianal disease)
- Montreal classification; Harvey-Bradshaw Index; CRP, calprotectin, albumin, nutritional markers
- Induction with corticosteroids (acute flare) or direct biologic therapy (moderate-severe disease)
- Maintenance with biologic ± immunomodulator (combination therapy for anti-TNF); treat-to-target
- Response assessment at 3–6 months: endoscopy, MRI, CRP, calprotectin
- Surgical consultation for stricture, abscess, fistula, or medically refractory disease
- Long-term: annual endoscopy for mucosal healing assessment; colorectal cancer surveillance (duration-dependent)
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $30,000 – $80,000 per year (branded biologics) — Save up to 90%
UK — NHS covered for residents; £5,000 – £20,000 private — Save up to 80%
UAE — $15,000 – $50,000 per year — Save up to 80%
India — $1,000 – $8,000 per year — Best value
Branded infliximab in the USA costs $25,000–$40,000 per year. Biosimilar infliximab (Remsima, Inflectra, or Indian-manufactured biosimilars) in India costs $1,500–$4,000 per year — identical in efficacy and safety to the originator biologic. Biosimilar adalimumab costs $800–$2,000 per year in India versus $20,000–$30,000 for branded Humira in the USA. For patients from countries without national insurance coverage for biologics, India's biosimilar availability is life-changing.
Recovery & Follow-up
Crohn's disease management is lifelong — it is not a condition with a 'recovery' but rather a programme of achieving and maintaining deep remission. With modern biologic therapy, approximately 40–60% of patients achieve endoscopic mucosal healing (the treat-to-target endpoint), which is associated with significantly reduced rates of hospitalisation, surgery, and bowel damage. Surgical recovery (laparoscopic ileocaecal resection) takes 4–6 weeks for full recovery.
Recovery Tips
- Take biologics on the prescribed schedule — missing doses risks loss of response and the development of anti-drug antibodies
- Stop smoking immediately — smoking significantly worsens Crohn's disease activity and reduces response to therapy
- Avoid NSAIDs (ibuprofen, naproxen) — they trigger Crohn's flares by disrupting gut mucosal integrity
- Attend calprotectin monitoring every 3 months during treatment — rising calprotectin predicts relapse before symptoms return, allowing early treatment adjustment
- Ensure influenza and pneumococcal vaccinations are up to date before starting biologics — biological therapy increases infection risk
Risks & Complications
Anti-TNF therapy risks: serious infection (including reactivation of latent tuberculosis — TB screening mandatory before starting); infusion reactions (infliximab) or injection site reactions (adalimumab); demyelination (rare); and a small increase in lymphoma risk with long-term anti-TNF + thiopurine combination therapy. All biologics increase the risk of opportunistic infections — standard screening and prophylaxis protocols are important. Surgical risks for bowel resection include anastomotic leak, short bowel syndrome (in patients requiring multiple resections), fistula, and intra-abdominal abscess.
Why GAF Healthcare
GAF Healthcare connects Crohn's disease patients with India's IBD-specialist gastroenterologists who are experienced in biological therapy management and treat-to-target monitoring strategies. For patients initiating biologic therapy, the full screening protocol (TB, hepatitis B, HIV) and vaccination programme is arranged before treatment. Biosimilar biologic prescriptions and infusion administration are coordinated at our partner centres' IBD infusion units for international patients visiting India for treatment.
Frequently Asked Questions
Can Crohn's disease be cured?
Crohn's disease currently has no cure — it is a lifelong condition requiring ongoing management. However, with modern biologic therapies and treat-to-target strategies, a significant proportion of patients achieve deep remission (mucosal and even transmural healing) that transforms their quality of life. The goal of current therapy is not just symptom control but prevention of bowel damage, disability, and surgery — treating the underlying inflammation before it causes irreversible bowel destruction.
Is surgery a cure for Crohn's disease?
Bowel resection surgery removes the diseased section of bowel and can provide prolonged remission — particularly for isolated ileocaecal Crohn's disease. However, Crohn's disease recurs at the surgical anastomosis in approximately 50–70% of patients within 5 years without post-operative medical therapy. Surgery is best thought of as a tool to manage complications (obstruction, fistula, abscess, medically refractory disease) and reset the disease burden — combined with post-operative biologic therapy to reduce recurrence risk. Post-operative prophylactic biologic therapy (infliximab or adalimumab) significantly reduces surgical recurrence rates.
What is perianal Crohn's disease and how is it treated?
Perianal Crohn's disease (pCD) — fistulae, abscesses, skin tags, and anal canal ulcers around the anus — is one of the most debilitating manifestations of Crohn's disease, present in approximately 25–35% of patients. Perianal fistulae in Crohn's are complex, recurrent, and notoriously difficult to heal. Treatment requires combined medical and surgical management: biological therapy with anti-TNF agents (infliximab achieves fistula closure in approximately 35–50% of patients); surgical drainage of perianal abscesses (urgent); loose seton sutures (draining the fistula track while the bowel inflammation is controlled); and in selected cases, Video-Assisted Anal Fistula Treatment (VAAFT) or LIFT procedure. MRI pelvis is essential for mapping fistula tract anatomy before any surgical intervention.